Ticker Details
NovoCure Limited Ordinary Shares NovoCure Ltd is a medical systems developer in the United States. Its primary product is the TTFields delivery system, which is a low-intensity therapy to combat acute tumors.
IPO Date:	September 28, 2015
Sector:	Healthcare
Industry:	Medical Instruments and Supplies
Market Cap:	$1.99B
Activated in VL:	True

Average Daily Range
Avg Daily Range:	$1.40 | 3.04%
Avg Daily Range (30 D):	$0.63 | 3.75%
Avg Daily Range (90 D):	$0.60 | 3.76%

Institutional Daily Volume
Avg Daily Volume:	.84M
Avg Daily Volume (30 D):	1.35M
Avg Daily Volume (90 D):	1.34M

Trade Size
Avg Trade Size (Sh.):	71
Avg Trade Size (Sh.) (30 D):	71
Avg Trade Size (Sh.) (90 D):	64

Institutional Trades
Total Institutional Trades:	5,391
Avg Institutional Trade:	$3.56M
Avg Institutional Trade (30 D):	$3.66M
Avg Institutional Trade (90 D):	$3.27M
Avg Institutional Trade Volume:	.08M
Avg Institutional Trades (Per Day):	2

Market Closing Trades
Avg Closing Trade:	$5.25M
Avg Closing Trade (30 D):	$3.43M
Avg Closing Trade (90 D):	$4.06M
Avg Closing Volume:	119.48K

News

Jun 4, 2026 @ 4:39 PM Stock Market Today, June 4: Broadcom Drags on Nasd... Source: Emma Newbery

May 27, 2026 @ 5:00 PM Glioblastoma Multiforme Market Poised for Signific... Source: Delveinsight

Feb 17, 2026 @ 4:17 PM New Treatment Modalities Are Reaching Cancers That... Source: Prnewswire

Feb 13, 2026 @ 12:34 PM Soleus Adds a Significant Number of Celcuity Share... Source: Lawrence Rothman, Cfa

Feb 12, 2026 @ 5:57 PM FDA Approves First-of-Its-Kind Device to Treat Pan... Source: U.S. Food And Drug Administration

Financials
	TTM	Q1 2026	Q4 2025
Basic EPS	$-.13	$-.62	$-.22
Diluted EPS	$-.13	$-.62	$-.22
Revenue	$183.58M	$174.06M	$174.35M
Gross Profit	$142.48M	$135.13M	$132.19M
Net Income / Loss	$-15.66M	$-71.14M	$-24.5M
Operating Income / Loss	$-10.56M	$-67.42M	$-40.39M
Cost of Revenue	$41.11M	$38.93M	$42.16M
Net Cash Flow	$6.29M	$-6.07M	$-241.25M
PE Ratio